Skip to Content
  • Previous Rank78
  • Revenues ($M)$42,294.0
  • Revenue Percent Change5.4%
  • Profits ($M)$6,220.0
  • Profits Percent Change159.8%
  • Assets ($M)$82,637.0
  • Employees69,000

Merck started 2019 strong, grabbing $10.8 billion in global sales during the first quarter—an 8% increase year-over-year—and raising its full-year revenue range for the year. This builds off the $42.3 billion in global sales the pharmaceutical giant netted in 2018, a 5% increase from 2017. Merck’s blockbuster cancer immunotherapy drug Keytruda continues to shine amongst its portfolio. Accounting for nearly a quarter of the company’s pharmaceutical sales, Keytruda netted $2.3 billion in sales for the first quarter in 2019. Merck is currently looking forward to the results of additional Keytruda studies later this year.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

Kenneth C. Frazier
CEO Title
Chairman, President & Chief Executive Officer
Health Care
HQ Location
Kenilworth, N.J.
Years on Fortune 500 List65

Merck Rank History

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$42,294.05.4%
Profits ($M)$6,220.0159.8%
Assets ($M)$82,637.0-
Total Stockholder Equity ($M)$26,701.0-

Profit Ratios

Profit as % of Revenues14.7%
Profits as % of Assets7.5%
Profits as % of Stockholder Equity23.3%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)2.32
EPS % Change (from 2017)166.7%
EPS % Change (5 year annual rate)9.6%
EPS % Change (10 year annual rate)-4.4%

Total Return

Total Return to Investors (2018)40.2%
Total Return to Investors (5 year, annualized)12.3%
Total Return to Investors (10 year, annualized)13.8%